On September 7, 2015 Innate Pharma SA (the "Company" – Euronext Paris: FR0010331421 – IPH) reported that Professor Martine Bagot, Head of the Dermatology Department at the Saint-Louis Hospital in Paris and co-discoverer of the target KIR3DL2, will present the rationale of IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody for the treatment of CTCL, as well as the protocol of the upcoming Phase I trial at the EORTC cutaneous lymphoma task force meeting (September 25-27, 2015 in Turin, Italy) (Press release, Innate Pharma, SEP 5, 2015, http://innate-pharma.com/en/news-events/presentation-iph4102-rationale-and-phase-i-protocol-be-presented-upcoming-eortc-cutaneous-lymphoma-task-force-meeting [SID:1234507402]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation title: "A novel targeted immunotherapy for CTCL: anti-KIR3DL2 mAb IPH4102 is potent and safe in non-clinical studies"
Session Name: Neil-Smith memorial lecture
Date: Saturday, September 26, 2015
Presentation Time: 12:30 AM – 1:00 PM